1832 Asset Management
TGTX icon

1832 Asset Management’s TG Therapeutics TGTX Stock Holding History

1832 Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-144,000
Closed -$5.18M – 714
2025
Q2 		$5.18M Sell
144,000
-1,339,800
-90% -$49.9M ﹤0.01% 372
2025
Q1 		$58.5M Sell
1,483,800
-171,300
-10% -$5.76M 0.05% 176
2024
Q4 		$49.8M Buy
+1,655,100
New +$47.5M 0.04% 185

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

1832 Asset Management's TGTX Position: Q3 2025 in Review

1832 Asset Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 144,000 shares — an estimated $5.18M sold.

1832 Asset Management first reported a position in TGTX in Q4 2024 and held it in 3 quarters. The position peaked at $58.5M in Q1 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • 1832 Asset Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • 1832 Asset Management sold 144,000 TG Therapeutics shares in Q3 2025, an estimated $5.18M.
  • 1832 Asset Management first reported a position in TG Therapeutics in Q4 2024 and held it in 3 quarters.
  • 1832 Asset Management's TG Therapeutics position peaked at $58.5M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on 1832 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.